Immunovant IncNASDAQ:IMVT
- LAST PRICE29.2300
- TODAY'S CHANGE (%)-0.3600 (-1.2166%)
- Bid / Lots29.0000/ 1
- Ask / Lots32.0000/ 1
- Open / Previous Close29.5900 / 29.5900
- Day Range
- 52 Week Range
- Volume1,959,206
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMVT |
|---|---|---|
| 09:32 ET | 102486 | 29.59 |
| 09:36 ET | 1600 | 29.53 |
| 09:38 ET | 2000 | 29.53 |
| 09:39 ET | 1400 | 29.42 |
| 09:41 ET | 914 | 29.495 |
| 09:43 ET | 500 | 29.44 |
| 09:48 ET | 2844 | 29.32 |
| 09:52 ET | 100 | 29.29 |
| 09:54 ET | 300 | 29.28 |
| 09:56 ET | 1293 | 29.2 |
| 09:57 ET | 2025 | 29.29 |
| 09:59 ET | 1435 | 29.48 |
| 10:01 ET | 6354 | 29.6 |
| 10:03 ET | 500 | 29.635 |
| 10:06 ET | 1900 | 29.45 |
| 10:08 ET | 609 | 29.5 |
| 10:10 ET | 1800 | 29.43 |
| 10:12 ET | 1702 | 29.43 |
| 10:14 ET | 9536 | 29.3 |
| 10:15 ET | 3364 | 29.31 |
| 10:17 ET | 9800 | 29.375 |
| 10:19 ET | 1900 | 29.555 |
| 10:21 ET | 1100 | 29.55 |
| 10:24 ET | 4305 | 29.41 |
| 10:26 ET | 1400 | 29.415 |
| 10:28 ET | 552 | 29.39 |
| 10:30 ET | 300 | 29.39 |
| 10:32 ET | 4672 | 29.385 |
| 10:33 ET | 1900 | 29.38 |
| 10:35 ET | 5271 | 29.47 |
| 10:37 ET | 600 | 29.47 |
| 10:39 ET | 2390 | 29.47 |
| 10:42 ET | 3798 | 29.44 |
| 10:44 ET | 3000 | 29.505 |
| 10:46 ET | 2800 | 29.485 |
| 10:48 ET | 3500 | 29.485 |
| 10:50 ET | 1400 | 29.48 |
| 10:51 ET | 4900 | 29.48 |
| 10:53 ET | 1446 | 29.455 |
| 10:55 ET | 900 | 29.475 |
| 10:57 ET | 700 | 29.54 |
| 11:00 ET | 5300 | 29.52 |
| 11:02 ET | 1000 | 29.53 |
| 11:04 ET | 1713 | 29.52 |
| 11:06 ET | 700 | 29.4625 |
| 11:08 ET | 52950 | 29.605 |
| 11:09 ET | 56689 | 29.47 |
| 11:11 ET | 508 | 29.43 |
| 11:13 ET | 200 | 29.495 |
| 11:15 ET | 1400 | 29.52 |
| 11:18 ET | 3650 | 29.495 |
| 11:20 ET | 6014 | 29.44 |
| 11:22 ET | 3259 | 29.47 |
| 11:24 ET | 900 | 29.5 |
| 11:26 ET | 544 | 29.5 |
| 11:27 ET | 2900 | 29.635 |
| 11:29 ET | 300 | 29.635 |
| 11:31 ET | 600 | 29.645 |
| 11:33 ET | 10281 | 29.495 |
| 11:36 ET | 800 | 29.515 |
| 11:38 ET | 700 | 29.51 |
| 11:40 ET | 800 | 29.575 |
| 11:42 ET | 550 | 29.68 |
| 11:44 ET | 1900 | 29.725 |
| 11:45 ET | 6850 | 29.66 |
| 11:47 ET | 12656 | 29.6 |
| 11:49 ET | 2300 | 29.59 |
| 11:51 ET | 500 | 29.585 |
| 11:54 ET | 1900 | 29.58 |
| 11:56 ET | 1201 | 29.61 |
| 11:58 ET | 100 | 29.595 |
| 12:00 ET | 1247 | 29.625 |
| 12:02 ET | 500 | 29.605 |
| 12:03 ET | 100 | 29.605 |
| 12:05 ET | 100 | 29.605 |
| 12:07 ET | 1412 | 29.68 |
| 12:09 ET | 700 | 29.69 |
| 12:12 ET | 8537 | 29.665 |
| 12:14 ET | 3817 | 29.615 |
| 12:16 ET | 400 | 29.615 |
| 12:18 ET | 700 | 29.615 |
| 12:20 ET | 1600 | 29.615 |
| 12:21 ET | 567 | 29.615 |
| 12:23 ET | 4671 | 29.605 |
| 12:25 ET | 200 | 29.605 |
| 12:27 ET | 900 | 29.605 |
| 12:30 ET | 8644 | 29.478 |
| 12:32 ET | 700 | 29.48 |
| 12:34 ET | 100 | 29.48 |
| 12:36 ET | 1280 | 29.48 |
| 12:38 ET | 200 | 29.47 |
| 12:39 ET | 500 | 29.475 |
| 12:41 ET | 500 | 29.47 |
| 12:43 ET | 200 | 29.48 |
| 12:45 ET | 650 | 29.5 |
| 12:48 ET | 1893 | 29.485 |
| 12:50 ET | 9655 | 29.56 |
| 12:52 ET | 720 | 29.56 |
| 12:54 ET | 200 | 29.54 |
| 12:56 ET | 200 | 29.54 |
| 12:57 ET | 6164 | 29.5 |
| 12:59 ET | 500 | 29.48 |
| 01:01 ET | 300 | 29.48 |
| 01:03 ET | 1100 | 29.485 |
| 01:06 ET | 800 | 29.51 |
| 01:08 ET | 2144 | 29.54 |
| 01:10 ET | 5900 | 29.58 |
| 01:12 ET | 700 | 29.595 |
| 01:14 ET | 1100 | 29.58 |
| 01:15 ET | 1900 | 29.58 |
| 01:17 ET | 300 | 29.58 |
| 01:19 ET | 1500 | 29.595 |
| 01:21 ET | 1600 | 29.62 |
| 01:24 ET | 9937 | 29.53 |
| 01:26 ET | 1000 | 29.58 |
| 01:28 ET | 500 | 29.58 |
| 01:30 ET | 1807 | 29.565 |
| 01:32 ET | 700 | 29.59 |
| 01:33 ET | 8262 | 29.56 |
| 01:35 ET | 1768 | 29.565 |
| 01:37 ET | 1000 | 29.585 |
| 01:39 ET | 1900 | 29.585 |
| 01:42 ET | 1416 | 29.63 |
| 01:44 ET | 3242 | 29.515 |
| 01:46 ET | 500 | 29.525 |
| 01:48 ET | 1900 | 29.51 |
| 01:50 ET | 12867 | 29.375 |
| 01:51 ET | 700 | 29.415 |
| 01:53 ET | 400 | 29.405 |
| 01:55 ET | 300 | 29.405 |
| 01:57 ET | 850 | 29.39 |
| 02:00 ET | 1500 | 29.38 |
| 02:02 ET | 1011 | 29.38 |
| 02:04 ET | 700 | 29.385 |
| 02:06 ET | 3050 | 29.32 |
| 02:08 ET | 600 | 29.335 |
| 02:09 ET | 100 | 29.335 |
| 02:11 ET | 700 | 29.335 |
| 02:13 ET | 1750 | 29.41 |
| 02:15 ET | 200 | 29.42 |
| 02:18 ET | 100 | 29.43 |
| 02:20 ET | 2068 | 29.43 |
| 02:22 ET | 38071 | 29.335 |
| 02:24 ET | 700 | 29.315 |
| 02:26 ET | 500 | 29.305 |
| 02:27 ET | 100 | 29.35 |
| 02:29 ET | 2300 | 29.34 |
| 02:31 ET | 700 | 29.345 |
| 02:33 ET | 2400 | 29.31 |
| 02:36 ET | 1700 | 29.32 |
| 02:38 ET | 200 | 29.325 |
| 02:40 ET | 400 | 29.335 |
| 02:42 ET | 2401 | 29.435 |
| 02:44 ET | 750 | 29.43 |
| 02:45 ET | 816 | 29.455 |
| 02:47 ET | 1091 | 29.5 |
| 02:49 ET | 5605 | 29.44 |
| 02:51 ET | 731 | 29.465 |
| 02:54 ET | 600 | 29.47 |
| 02:56 ET | 950 | 29.475 |
| 02:58 ET | 1700 | 29.5 |
| 03:00 ET | 3497 | 29.465 |
| 03:02 ET | 9151 | 29.51 |
| 03:03 ET | 1766 | 29.5 |
| 03:05 ET | 2027 | 29.44 |
| 03:07 ET | 1598 | 29.435 |
| 03:09 ET | 616 | 29.435 |
| 03:12 ET | 1050 | 29.47 |
| 03:14 ET | 1823 | 29.49 |
| 03:16 ET | 1300 | 29.46 |
| 03:18 ET | 1752 | 29.43 |
| 03:20 ET | 800 | 29.39 |
| 03:21 ET | 700 | 29.42 |
| 03:23 ET | 900 | 29.415 |
| 03:25 ET | 1150 | 29.4 |
| 03:27 ET | 2560 | 29.44 |
| 03:30 ET | 750 | 29.425 |
| 03:32 ET | 1808 | 29.41 |
| 03:34 ET | 2318 | 29.39 |
| 03:36 ET | 1607 | 29.37 |
| 03:38 ET | 1781 | 29.395 |
| 03:39 ET | 3373 | 29.435 |
| 03:41 ET | 700 | 29.41 |
| 03:43 ET | 13149 | 29.4 |
| 03:45 ET | 2500 | 29.41 |
| 03:48 ET | 2650 | 29.365 |
| 03:50 ET | 2764 | 29.41 |
| 03:52 ET | 5244 | 29.51 |
| 03:54 ET | 12578 | 29.445 |
| 03:56 ET | 6582 | 29.41 |
| 03:57 ET | 27723 | 29.25 |
| 03:59 ET | 906117 | 29.23 |
Sep 10, 2024
DJ Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co., from 7:25AM ET on Tuesday Sep 10, 2024 by Dow Jones
7:25AM ET on Tuesday Sep 10, 2024 by Dow Jones
Sep 9, 2024
Roivant Provides Update on Graves' Disease Development Program, from 7:00AM ET on Monday Sep 09, 2024 by Dow Jones
7:00AM ET on Monday Sep 09, 2024 by Dow JonesImmunovant Provides Update on Graves' Disease Development Program, from 3:55AM ET on Monday Sep 09, 2024 by Dow Jones
3:55AM ET on Monday Sep 09, 2024 by Dow Jones
Sep 5, 2024
Immunovant to Host Graves' Disease Program Update on September 9, 2024, from 6:30AM ET on Thursday Sep 05, 2024 by Dow Jones
6:30AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Immunovant Inc | 4.3B | -15.3x | --- |
Crinetics Pharmaceuticals Inc | 4.3B | -14.1x | --- |
Biohaven Ltd | 3.8B | -4.4x | --- |
Dyne Therapeutics Inc | 3.7B | -10.2x | --- |
BridgeBio Pharma Inc | 5.0B | -10.1x | --- |
MoonLake Immunotherapeutics | 3.4B | -59.8x | --- |
Company Information
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Contact Information
- Headquarters
- 320 West 37Th StreetNEW YORK, NY, United States 10018
- Phone
- 917-580-3099
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board
- Frank Torti
- Chief Executive Office, Director
- Peter Salzmann
- Chief Financial Officer
- Eva Barnett
- Chief Technology Officer
- Jay Stout
- Chief Development Officer
- Julia Butchko
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.3B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 146.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-1.92 |
Book Value | $4.24 |
P/E Ratio | -15.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
